Explore

Trendline Trendline
Silexion Therapeutics Reports Increased Net Loss Amid R Expansion for SIL204

Silexion Therapeutics Reports Increased Net Loss Amid R Expansion for SIL204

Silexion Therapeutics Reports Increased Net Loss Amid R Expansion for SIL204
Trendline Trendline
Inmune Bio to Release Year-End 2025 Financial Results, Impacting Investor Sentiment

Inmune Bio to Release Year-End 2025 Financial Results, Impacting Investor Sentiment

Inmune Bio to Release Year-End 2025 Financial Results, Impacting Investor Sentiment
Trendline Trendline
Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule

Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule

Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule
Trendline Trendline
CervoMed Faces Financial Challenges Amid Clinical Advancements

CervoMed Faces Financial Challenges Amid Clinical Advancements

CervoMed Faces Financial Challenges Amid Clinical Advancements
Trendline Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
Trendline Trendline
CervoMed Reports $7.96M Net Loss in Q1 2026 Amid Clinical Investments

CervoMed Reports $7.96M Net Loss in Q1 2026 Amid Clinical Investments

CervoMed Reports $7.96M Net Loss in Q1 2026 Amid Clinical Investments
Trendline Trendline
Suncrete Reports 64% Revenue Increase in Q1 2026 Amid Strategic Expansion

Suncrete Reports 64% Revenue Increase in Q1 2026 Amid Strategic Expansion

Suncrete Reports 64% Revenue Increase in Q1 2026 Amid Strategic Expansion
Trendline Trendline
Suncrete Reports Q1 2026 Earnings with Significant Revenue Growth and Strategic Acquisitions

Suncrete Reports Q1 2026 Earnings with Significant Revenue Growth and Strategic Acquisitions

Suncrete Reports Q1 2026 Earnings with Significant Revenue Growth and Strategic Acquisitions
Trendline Trendline
Suncrete Reports 64% Revenue Increase in Q1 2026, Expands Operations

Suncrete Reports 64% Revenue Increase in Q1 2026, Expands Operations

Suncrete Reports 64% Revenue Increase in Q1 2026, Expands Operations
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses
Trendline Trendline
Cerebras Systems' Shares Surge 89% in IPO Amid AI Investment Boom

Cerebras Systems' Shares Surge 89% in IPO Amid AI Investment Boom

Cerebras Systems' Shares Surge 89% in IPO Amid AI Investment Boom
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss